Sugi Predict

Sugi Predict / Compounds / SCHEMBL375264

SCHEMBL375264

SCHEMBL375264

c1ccc(CNC2CCOCC2)cc1

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GRIN2B Q13224 4/20 0.62
▸ MEN1 O00255 2/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ RAB9A P51151 1/20 0.58
▸ ACHE P22303 6/20 0.57
▸ BACE1 P56817 6/20 0.57
▸ BCHE P06276 4/20 0.57
▸ OPRM1 P35372 3/20 0.51
▸ OPRL1 P41146 2/20 0.51
▸ CARM1 Q86X55 1/20 0.50
▸ PRMT6 Q96LA8 1/20 0.50
▸ OPRK1 P41145 1/20 0.50
▸ FYN P06241 1/20 0.49
▸ HRH3 Q9Y5N1 1/20 0.47
▸ FABP6 P51161 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL375157 0.90 MEN1 (0.75) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL32675244 0.89 GRIN2B (0.54) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL3937405 0.89 GRIN2B (0.54) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL663239 0.86 GRIN2B (0.74) GRIN2BMEN1KMT2ARAB9AACHE
Hydrochloric Acid SCHEMBL2550113 0.84 MEN1 (0.78) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL433970 0.82 GRIN2B (0.69) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL2954218 0.82 GRIN2B (0.69) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL4173336 0.82 GRIN2B (0.69) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL374658 0.82 ALDH1A1 (0.55) GRIN2BMEN1KMT2AACHEBACE1
SCHEMBL25033800 0.81 HRH3 (0.49) GRIN2BMEN1KMT2ARAB9AACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106458996-A Fused pyrimidines as inhibitors of the p97 complex 克里弗生物科学公司 2017-02-22 — — CN claimed
EP-3097092-A1 FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX Cleave Biosciences, Inc. (US) 2016-11-30 — — EP claimed
WO-2015109285-A1 FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX CLEAVE BIOSCIENCES, INC. (US) 2015-07-23 — — WO claimed
CN-111905836-B Porous plastic chemical reagent carrier and preparation method and application thereof 上海组波智能仪器科技有限公司 2024-08-13 — — CN disclosed
US-20230112832-A1 Chemokine CXCR4 Receptor Modulators and Uses Related Thereto UNIV EMORY (US) 2023-04-13 — — US disclosed
CN-111905836-A Porous plastic chemical reagent carrier and preparation method and application thereof 上海组波智能仪器科技有限公司 2020-11-10 — — CN disclosed
US-20200054623-A1 Chemokine CXCR4 Receptor Modulators and Uses Related Thereto EMORY UNIVERSITY 2020-02-20 — — US disclosed
WO-2019113419-A1 PYRANO[3,4-B]PYRAZINE KAPPA OPIOID RECEPTOR LIGANDS FOR TREATING ADDICTION, PRURITUS, PAIN, AND INFLAMMATION THE ROCKEFELLER UNIVERSITY (US) 2019-06-13 — — WO disclosed
CN-107459508-A Annelated pyrimidines as the inhibitor of P97 compounds 克里弗生物科学公司 2017-12-12 — — CN disclosed
EP-3083597-B1 FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS GRUENENTHAL GMBH (DE) 2017-11-22 — — EP disclosed
CN-104768946-B Fused pyrimidines as inhibitors of the p97 complex 克里弗生物科学公司 2017-05-03 — — CN disclosed
EP-2409976-A1 GLYCINE TRANSPORTER INHIBITOR Taisho Pharmaceutical Co., Ltd. (JP) 2012-01-25 — — EP disclosed
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 — — US disclosed
US-20090099195-A1 Therapeutic Compounds 570 ASTRAZENECA AB (SE) 2009-04-16 — — US disclosed
EP-1421084-B1 POLYCYCLIC GUANINE PHOSPHODIESTERASE V INHIBITORS SCHERING CORP (US) 2008-05-14 — — EP disclosed
EP-1790652-A1 Polycyclic guanine phosphodiesterase V inhibitors Schering Corporation (US) 2007-05-30 — — EP disclosed
US-6969719-B2 Polycyclic guanine phosphodiesterase V inhibitors SCHERING CORPORATION (US) 2005-11-29 — — US disclosed
EP-1421084-A1 POLYCYCLIC GUANINE PHOSPHODIESTERASE V INHIBITORS Schering Corporation (US) 2004-05-26 — — EP disclosed
US-20030153587-A1 Polycyclic guanine phosphodiesterase V inhibitors SCHERING CORPORATION 2003-08-14 — — US disclosed
WO-2003020724-A1 POLYCYCLIC GUANINE PHOSPHODIESTERASE V INHIBITORS SCHERING CORPORATION (US) 2003-03-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200054623-A1 Chemokine CXCR4 Receptor Modulators and Uses Related Thereto CXCR4, CXCL12, CXCR1 GRIN2B 2480/4885MEN1 4543/4885KMT2A 4253/4885
US-20090099195-A1 Therapeutic Compounds 570 OPRL1, OPRK1, OPRM1 GRIN2B 671/4885MEN1 2623/4885KMT2A 3628/4885
US-20030153587-A1 Polycyclic guanine phosphodiesterase V inhibitors PDE5A, PDE3A, PDE2A GRIN2B 673/4885MEN1 2305/4885KMT2A 3124/4885
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES SLC18A2, SLC1A2, SLC6A1 GRIN2B 29/4885MEN1 2688/4885KMT2A 3137/4885
US-20230112832-A1 Chemokine CXCR4 Receptor Modulators and Uses Related Thereto CXCR4, CXCL12, CXCR1 GRIN2B 2480/4885MEN1 4543/4885KMT2A 4253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.